{"id":"doi:10.1056/nejmoa2500969","kind":"article","title":"Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity","authors":["Sean Wharton","Ildiko Lingvay","Paweł Bogdański","Ruben Duque do Vale","Stephan Jacob","Tobias Karlsson","C. Shaji","Domenica Rubino","William Timothy Garvey"],"author_count":9,"year":2025,"published":"2025-09-17","venue":"New England Journal of Medicine","cited_by":140,"doi":"10.1056/nejmoa2500969","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1056/nejmoa2500969","archive_url":"https://space-kitty.com/papers/doi:10.1056/nejmoa2500969","updated":null,"pmid":"40934115","pmcid":null,"openalex_id":"W4414160143","pdf_url":null,"abstract":null,"abstract_license":null,"license":null,"is_open_access":false,"retracted":false,"peer_reviewed":null,"categories":["Pharmacology and Obesity Treatment"],"details":null,"provenance":"openalex","attribution":"Metadata and citation counts: OpenAlex (CC0).","topics":[{"slug":"glp1-metabolic","name":"GLP-1 & Incretin Therapies","domain_slug":"medicine"}],"cited_in_dossiers":[{"slug":"glp1-metabolic","title":"GLP-1 & Incretin Therapies: State of the Field (October 2026)","url":"https://space-kitty.com/dossiers/glp1-metabolic"}]}